SCHEMBL3186013

SCHEMBL3186013

CCCCc1ccc(C(C)=O)s1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.66
LMNA P02545 3/20 0.66
RECQL P46063 2/20 0.66
PRNP P04156 1/20 0.66
RXFP1 Q9HBX9 1/20 0.66
HPGD P15428 4/20 0.60
POLB P06746 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
TSHR P16473 2/20 0.47
GSK3B P49841 1/20 0.46
MAPT P10636 4/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
HTT P42858 2/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3193059 0.95 ALDH1A1 (0.69) ALDH1A1LMNARECQLPRNPRXFP1
SCHEMBL3176363 0.93 LMNA (0.71) ALDH1A1LMNARECQLPRNPRXFP1
SCHEMBL3199622 0.89 ALDH1A1 (0.60) ALDH1A1LMNARECQLPRNPRXFP1
SCHEMBL261238 0.85 POLB (0.54) ALDH1A1LMNARECQLPRNPRXFP1
SCHEMBL13838138 0.82 LMNA (0.88) ALDH1A1LMNARECQLPRNPRXFP1
SCHEMBL3582862 0.82 POLB (0.51) ALDH1A1LMNARECQLPRNPRXFP1
SCHEMBL4058053 0.81 ALDH1A1 (0.60) ALDH1A1LMNARECQLPRNPRXFP1
SCHEMBL7211399 0.81 HPGD (0.54) ALDH1A1LMNARECQLPRNPRXFP1
SCHEMBL3583665 0.81 POLB (0.47) ALDH1A1LMNARECQLPRNPRXFP1
SCHEMBL1798146 0.80 ALDH1A1 (0.56) ALDH1A1LMNARECQLPRNPRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3176162-A1 DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS Cayman Chemical Company, Incorporated (US) 2017-06-07 EP disclosed
US-20120289495-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals Inc. 2012-11-15 US disclosed
US-7659411-B2 Process for producing 2-acylthiophene compound SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2010-02-09 US disclosed
CN-100455578-C Process for producing 2-acylthiophene compound SUMITOMO SEIKA CHEMICALS (JP) 2009-01-28 CN disclosed
US-20070149787-A1 Process for producing 2-acylthiophene compound SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2007-06-28 US disclosed
CN-1886396-A Process for producing 2-acylthiophene compound SUMITOMO SEIKA CHEMICALS (JP) 2006-12-27 CN disclosed
EP-1695972-A1 PROCESS FOR PRODUCING 2-ACYLTHIOPHENE COMPOUND SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2006-08-30 EP disclosed
US-6616989-B1 A switching and/or display device CLARIANT INTERNATIONAL LTD. (CH) 2003-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149787-A1 Process for producing 2-acylthiophene compound AGPAT2, MOGAT2, TPST2 ALDH1A1 111/4885LMNA 4557/4885RECQL 2912/4885
US-20120289495-A1 COMPOUNDS AND METHODS XDH, CCNY, TOP2B ALDH1A1 1319/4885LMNA 222/4885RECQL 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.